RMD on NYSE
Logo: Smoothape~commonswiki, CC0, via Wikimedia Commons4
Medical equipment company
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.3 It was founded by Peter Farrell.1 Its chief executive is Michael Farrell.1 Its shares trade on NYSE under the symbol RMD.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Compare with Dexcom, Solventum or MiniMed Group, Inc., or pick any stock.
See how the biggest companies compare on our leaderboards
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers (i.e. home health, hospice, skilled nursing facilities, life plan communities, senior living centers, and private duty).3
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue by product, business segment and region, as the company reports it to the SEC.
Sleep and Breathing Health brought in 88% of the revenue ResMed broke down this way in fiscal 2026.
| Products and services | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sleep and Breathing Health | $4.1B | $4.5B | $5.0B |
| Residential Care Software | $584.1M | $641.4M | $675.8M |
Sleep and Breathing Health brought in 88% of the revenue ResMed broke down this way in fiscal 2026.
| Business segments | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sleep and Breathing Health | $4.1B | $4.5B | $5.0B |
| Residential Care Software | $584.1M | $641.4M | $675.8M |
United States brought in 63% of the revenue ResMed broke down this way in fiscal 2026.
| Regions | 2024 | 2025 | 2026 |
|---|---|---|---|
| United States | $3.0B | $3.3B | $3.6B |
| Outside the United States | $1.7B | $1.9B | $2.1B |
Out of $5.7B in revenue.5
Out of $1.8B of cash from operations.5
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Net revenue | $5.7B | $5.1B | $4.7B |
| Cost of sales (exclusive of amortization shown separately below) | $2.2B | $2.1B | $2.0B |
| Amortization of acquired intangible assets | $31.8M | $32.1M | $33.0M |
| Total cost of sales | $2.2B | $2.1B | $2.0B |
| Gross profit | $3.5B | $3.1B | $2.7B |
| Research and development | $378.3M | $331.3M | $307.5M |
| Selling, general, and administrative | $1.1B | $993.0M | $917.1M |
| Amortization of acquired intangible assets | $45.5M | $45.3M | $46.5M |
| Restructuring expenses (note 17) | $21.7M | $0 | $64.2M |
| Total operating expenses | $1.6B | $1.4B | $1.3B |
| Income from operations | $1.9B | $1.7B | $1.3B |
| Interest income (expense), net | $49.9M | $4.1M | -$45.7M |
| Gain (loss) attributable to equity method investments (note 6) | $7.0M | $3.6M | -$1.8M |
| Gain (loss) on equity investments (note 6) | -$15.0M | -$10.3M | -$4.0M |
| Other, net | -$9.2M | -$5.3M | -$3.5M |
| Total other income (loss), net | $32.7M | -$7.8M | -$55.1M |
| Income before income taxes | $1.9B | $1.7B | $1.3B |
| Income taxes (note 12) | $396.1M | $276.8M | $243.8M |
| Net income | $1.5B | $1.4B | $1.0B |
| Basic earnings per share (note 11) (in dollars per share) | $10.47 | $9.55 | $6.94 |
| Diluted earnings per share (note 11) (in dollars per share) | $10.43 | $9.51 | $6.92 |
| Dividend declared per share (in dollars per share) | $2.40 | $2.12 | $1.92 |
| Basic shares outstanding (000's) (in shares) | 145.5M shares | 146.7M shares | 147.0M shares |
| Diluted shares outstanding (000's) (in shares) | 146.1M shares | 147.3M shares | 147.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 1997-04-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $1.5B | $1.2B | |||
| Accounts receivable, net of allowances of $25,839 and $22,424 at June 30, 2026 and June 30, 2025, respectively | $1.0B | $939.5M | |||
| Inventories (note 4) | $945.8M | $927.7M | |||
| Prepaid expenses and other current assets (note 4) | $416.1M | $429.0M | |||
| Assets held for sale (note 18) | $457.4M | $0 | |||
| Total current assets | $4.3B | $3.5B | |||
| Property, plant and equipment, net (note 4) | $581.8M | $550.8M | |||
| Operating lease right-of-use assets (note 9) | $153.2M | $167.5M | |||
| Goodwill (note 5) | $2.9B | $3.0B | |||
| Other intangible assets, net (note 5) | $452.7M | $464.9M | |||
| Deferred income taxes (note 12) | $329.3M | $253.1M | |||
| Prepaid taxes and other non-current assets | $214.6M | $185.8M | |||
| Total non-current assets | $4.6B | $4.7B | |||
| Total assets | $9.0B | $8.2B | |||
| Accounts payable | $308.9M | $278.2M | |||
| Accrued expenses (note 7) | $494.9M | $402.3M | |||
| Operating lease liabilities, current (note 9) | $29.1M | $30.5M | |||
| Deferred revenue | $162.9M | $166.0M | |||
| Income taxes payable (note 12) | $98.1M | $132.3M | |||
| Short-term debt, net (note 8) | $259.9M | $9.9M | |||
| Liabilities held for sale (note 18) | $41.2M | $0 | |||
| Total current liabilities | $1.4B | $1.0B | |||
| Deferred revenue | $171.0M | $156.8M | |||
| Deferred income taxes (note 12) | $64.6M | $77.7M | |||
| Operating lease liabilities, non-current (note 9) | $137.4M | $153.0M | |||
| Other long-term liabilities | $213.0M | $141.5M | |||
| Long-term debt, net (note 8) | $399.4M | $658.4M | |||
| Total non-current liabilities | $985.4M | $1.2B | |||
| Total liabilities | $2.4B | $2.2B | |||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | $0 | $0 | |||
| Common stock, $0.004 par value, 350,000,000 shares authorized; 191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | $764.0K | $761.0K | |||
| Additional paid-in capital | $2.2B | $2.0B | |||
| Retained earnings | $7.3B | $6.1B | |||
| Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025 | -$2.8B | -$2.1B | |||
| Accumulated other comprehensive loss | -$82.5M | -$74.7M | |||
| Total stockholders equity | $6.6B | $6.0B | $4.9B | $4.1B | |
| Total liabilities and stockholders equity | $9.0B | $8.2B | |||
| Accounts receivable, allowance for credit loss, current | $25.8M | $22.4M | |||
| Preferred stock at par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | |||
| Common stock, shares issued (in shares) | 191.0M shares | 190.3M shares | |||
| Common stock, shares outstanding (in shares) | 144.2M shares | 146.4M shares | |||
| Treasury stock, shares (in shares) | 46.8M shares | 43.9M shares |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 1997-04-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $1.5B | $1.2B | |||
| Accounts receivable, net of allowances of $25,839 and $22,424 at June 30, 2026 and June 30, 2025, respectively | $1.0B | $939.5M | |||
| Inventories (note 4) | $945.8M | $927.7M | |||
| Prepaid expenses and other current assets (note 4) | $416.1M | $429.0M | |||
| Assets held for sale (note 18) | $457.4M | $0 | |||
| Total current assets | $4.3B | $3.5B | |||
| Property, plant and equipment, net (note 4) | $581.8M | $550.8M | |||
| Operating lease right-of-use assets (note 9) | $153.2M | $167.5M | |||
| Goodwill (note 5) | $2.9B | $3.0B | |||
| Other intangible assets, net (note 5) | $452.7M | $464.9M | |||
| Deferred income taxes (note 12) | $329.3M | $253.1M | |||
| Prepaid taxes and other non-current assets | $214.6M | $185.8M | |||
| Total non-current assets | $4.6B | $4.7B | |||
| Total assets | $9.0B | $8.2B | |||
| Accounts payable | $308.9M | $278.2M | |||
| Accrued expenses (note 7) | $494.9M | $402.3M | |||
| Operating lease liabilities, current (note 9) | $29.1M | $30.5M | |||
| Deferred revenue | $162.9M | $166.0M | |||
| Income taxes payable (note 12) | $98.1M | $132.3M | |||
| Short-term debt, net (note 8) | $259.9M | $9.9M | |||
| Liabilities held for sale (note 18) | $41.2M | $0 | |||
| Total current liabilities | $1.4B | $1.0B | |||
| Deferred revenue | $171.0M | $156.8M | |||
| Deferred income taxes (note 12) | $64.6M | $77.7M | |||
| Operating lease liabilities, non-current (note 9) | $137.4M | $153.0M | |||
| Other long-term liabilities | $213.0M | $141.5M | |||
| Long-term debt, net (note 8) | $399.4M | $658.4M | |||
| Total non-current liabilities | $985.4M | $1.2B | |||
| Total liabilities | $2.4B | $2.2B | |||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | $0 | $0 | |||
| Common stock, $0.004 par value, 350,000,000 shares authorized; 191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | $764.0K | $761.0K | |||
| Additional paid-in capital | $2.2B | $2.0B | |||
| Retained earnings | $7.3B | $6.1B | |||
| Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025 | -$2.8B | -$2.1B | |||
| Accumulated other comprehensive loss | -$82.5M | -$74.7M | |||
| Total stockholders equity | $6.6B | $6.0B | $4.9B | $4.1B | |
| Total liabilities and stockholders equity | $9.0B | $8.2B | |||
| Accounts receivable, allowance for credit loss, current | $25.8M | $22.4M | |||
| Preferred stock at par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | |||
| Common stock, shares issued (in shares) | 191.0M shares | 190.3M shares | |||
| Common stock, shares outstanding (in shares) | 144.2M shares | 146.4M shares | |||
| Treasury stock, shares (in shares) | 46.8M shares | 43.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Net income | $1.5B | $1.4B | $1.0B |
| Depreciation and amortization | $201.3M | $198.5M | $176.9M |
| Amortization of right-of-use assets | $42.8M | $37.3M | $39.3M |
| Stock-based compensation costs (note 10) | $104.3M | $91.7M | $80.2M |
| (Gain) loss attributable to equity method investments, net of dividends received (note 6) | -$2.4M | -$3.6M | $1.8M |
| (Gain) loss on equity investments (note 6) | $15.0M | $10.3M | $4.0M |
| Gain on previously held equity investment (note 6) | -$4.4M | $0 | $0 |
| Restructuring expenses (note 17) | $0 | $0 | $33.2M |
| Accounts receivable | -$96.8M | -$76.7M | -$134.3M |
| Inventories | -$9.9M | -$80.2M | $172.2M |
| Prepaid expenses, net deferred income taxes and other current assets | -$140.3M | $82.6M | -$115.2M |
| Accounts payable, accrued expenses and other | $172.7M | $91.0M | $122.1M |
| Net cash provided by (used in) operating activities | $1.8B | $1.8B | $1.4B |
| Purchases of property, plant and equipment | -$156.3M | -$89.9M | -$99.5M |
| Patent registration costs | -$18.7M | -$10.8M | -$15.4M |
| Purchases of intangible assets | -$2.2M | $0 | $0 |
| Business acquisitions, net of cash acquired | -$350.7M | -$139.2M | -$133.5M |
| Purchases of investments (note 6) | -$28.5M | -$6.4M | -$12.8M |
| Proceeds from exits of investments (note 6) | $2.8M | $4.6M | $1.0M |
| Proceeds (payments) on maturity of foreign currency contracts | $8.5M | $41.6M | -$9.7M |
| Net cash provided by (used in) investing activities | -$545.2M | -$200.0M | -$269.8M |
| Proceeds from issuance of common stock, net | $74.5M | $74.4M | $53.1M |
| Taxes paid related to net share settlement of equity awards | -$21.8M | -$18.1M | -$8.8M |
| Purchases of treasury stock | -$700.0M | -$300.0M | -$150.0M |
| Payments of business combination contingent consideration | $0 | -$855.0K | -$1.3M |
| Acquisition of consolidated subsidiary | $0 | -$10.9M | $0 |
| Proceeds from borrowings, net of borrowing costs | $0 | $0 | $105.0M |
| Repayment of borrowings | -$10.0M | -$40.0M | -$835.0M |
| Dividends paid | -$349.7M | -$310.9M | -$282.3M |
| Net cash provided by (used in) financing activities | -$1.0B | -$606.3M | -$1.1B |
| Effect of exchange rate changes on cash | $6.2M | $25.8M | -$1.7M |
| Net increase (decrease) in cash and cash equivalents | $259.8M | $971.1M | $10.5M |
| Income taxes paid, net of refunds | $357.2M | $214.0M | $278.4M |
| Interest paid | $27.1M | $28.4M | $45.7M |
| Fair value of assets acquired, excluding cash | $151.2M | $43.5M | $46.0M |
| Liabilities assumed | -$11.8M | -$6.3M | -$7.7M |
| Goodwill on acquisition | $222.9M | $101.3M | $92.2M |
| Previously held equity investment | -$7.4M | $0 | $0 |
| Deferred payments | -$1.0M | $670.0K | -$143.0K |
| Fair value of contingent consideration | -$3.2M | $855.0K | $4.4M |
| Cash paid for acquisitions | $350.7M | $140.1M | $134.8M |
No quarter-by-quarter statement was filed.
ResMed sits at the top of its group. 30 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ResMed
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
What ResMed reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.3B5 Jun 30, 2026 | $1.3B5 Jun 30, 2025 | +6.1% |
| Accumulated depreciation | $751.0M5 Jun 30, 2026 | $705.3M5 Jun 30, 2025 | +6.5% |
| Property and equipment, net | $581.8M5 Jun 30, 2026 | $550.8M5 Jun 30, 2025 | +5.6% |
| Operating-lease assets (leased space) | $153.2M5 Jun 30, 2026 | $167.5M5 Jun 30, 2025 | −8.6% |
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $1.5B5 Jun 30, 2026 | $1.2B5 Jun 30, 2025 | +21.5% |
| Stakes in other companies (equity method) | $76.8M5 Jun 30, 2026 | $76.2M5 Jun 30, 2025 | +0.8% |
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $2.9B5 Jun 30, 2026 | $3.0B5 Jun 30, 2025 | −4.5% |
| Finite-lived intangibles, net | $452.7M5 Jun 30, 2026 | $464.9M5 Jun 30, 2025 | −2.6% |
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $945.8M5 Jun 30, 2026 | $927.7M5 Jun 30, 2025 | +2.0% |
| Raw materials | $396.1M5 Jun 30, 2026 | $367.3M5 Jun 30, 2025 | +7.9% |
| Work in process | $2.6M5 Jun 30, 2026 | $2.5M5 Jun 30, 2025 | +3.8% |
| Finished goods | $547.0M5 Jun 30, 2026 | $557.9M5 Jun 30, 2025 | −1.9% |
We conduct our operations in both owned and leased properties. Our principal executive offices and U.S. sales facilities consist of approximately 230,000 square feet and are located on Spectrum Center Boulevard in San Diego, California, in a building we own. We have our primary research and development facilities, as well as office and manufacturing facilities at our owned site in Sydney, Australia. Other facilities are in Atlanta, Georgia, Greenwood, Indiana, Moreno Valley, California, Chatsworth, California, and Calabasas, California, U.S.A.; Singapore; Johor Bahru, Malaysia; Lyon, France; Gremsdorf and Munich, Germany; and Suzhou, China.
We believe that our facilities meet the needs of our current business operations. At June 30, 2026, our principal owned and leased properties were as follows:
Location · Ownership Status(Owned / Leased) · SquareFootage · Primary Usage
San Diego, California · Owned · 230,000 · Corporate headquarters, engineering, research and development, sales and administration
Sydney, Australia · Owned · 437,000 · Manufacturing, engineering, research and development, sales and administration
Suzhou, China · Owned · 53,000 · Manufacturing, warehouse, engineering, research and development
Atlanta, Georgia · Leased · 467,000 · Manufacturing, warehouse and distribution
Greenwood, Indiana · Leased · 447,000 · Warehouse and distribution
Johor, Malaysia · Leased · 349,000 · Manufacturing, engineering, research and development
Singapore · Leased · 305,000 · Manufacturing, engineering, research and development, sales and administration
Moreno Valley, California · Leased · 244,000 · Warehouse and distribution
Lyon, France · Leased · 132,000 · Sales, manufacturing and distribution
Calabasas, California(1) · Leased · 129,000 · Manufacturing, engineering, research and development
Chatsworth, California(1) · Leased · 72,000 · Manufacturing, engineering, research and development
Atlanta, Georgia · Leased · 61,000 · Residential Care Software sales and administration, engineering, research and development
Gremsdorf, Germany · Leased · 51,000 · Warehouse and distribution, sales and administration
Munich, Germany · Leased · 46,000 · Sales and distribution
(1)Operations fully transitioned from our Chatsworth, California location to our Calabasas, California location during fiscal year 2027.
Item 2 of the 10-K filed Aug 13, 2026.17
Founded by Peter Farrell in 1989.1
Resmed was established in June 1989 by Peter Farrell in Australia. The company opened an office in San Diego in 1992, and made that its headquarters two years later when it incorporated in the US.
From Wikipedia’s article on ResMed, shared under CC BY-SA 4.0.7
Who has led ResMed, and when. Pick a name to see everywhere that person has worked.
From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
In January 2020, Resmed Inc. agreed to pay more than $37.5 million to resolve alleged kickbacks paid to durable medical equipment suppliers, sleep labs, and other healthcare providers in violation of the Anti-Kickback Statute.
From Wikipedia’s article on ResMed, shared under CC BY-SA 4.0.7
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
608 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 368 insider forms, 13 large holders, 167 other. The latest 20:
The 608 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
203 open-market trades by officers, directors and large owners since October 2021: 0 buys and 203 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $222.44 | $1.1M | Form 4 |
| Sep 2, 2026 | FARRELL PETER CDirector | Sale | 970 | $234.73 | $227.7K | Form 4 |
| Aug 7, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $205.69 | $1.0M | Form 4 |
| Aug 5, 2026 | FARRELL PETER CDirector | Sale | 8,000 | $225.00 | $1.8M | Form 4 |
| Jul 7, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $218.55 | $1.1M | Form 4 |
| Jun 8, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $193.96 | $968.1K | Form 4 |
| May 7, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $207.82 | $1.0M | Form 4 |
| Apr 7, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $225.50 | $1.1M | Form 4 |
| Apr 1, 2026 | Sandercock BrettChief Financial Officer | Sale | 1,000 | $224.31 | $224.3K | Form 4 |
| Apr 1, 2026 | FARRELL PETER CDirector | Sale | 2,000 | $225.00 | $450.0K | Form 4 |
| Mar 9, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $251.03 | $1.3M | Form 4 |
| Mar 4, 2026 | FARRELL PETER CDirector | Sale | 2,000 | $260.22 | $520.4K | Form 4 |
| Mar 2, 2026 | Sandercock BrettChief Financial Officer | Sale | 1,000 | $254.30 | $254.3K | Form 4 |
| Feb 9, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $273.78 | $1.4M | Form 4 |
| Feb 4, 2026 | FARRELL PETER CDirector | Sale | 2,000 | $251.31 | $502.6K | Form 4 |
| Feb 4, 2026 | Rider Michael JGlobal General Counsel | Sale | 50 | $260.00 | $13.0K | Form 4 |
| Feb 2, 2026 | Sandercock BrettChief Financial Officer | Sale | 1,000 | $257.03 | $257.0K | Form 4 |
| Jan 7, 2026 | FARRELL PETER CDirector | Sale | 2,000 | $248.83 | $497.7K | Form 4 |
| Jan 7, 2026 | Farrell Michael J.Chairman and CEO | Sale | 4,991 | $248.46 | $1.2M | Form 4 |
| Jan 2, 2026 | Sandercock BrettChief Financial Officer | Sale | 1,000 | $241.75 | $241.8K | Form 4 |
All 203 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
ResMed has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2026 | Michael Farrell | 54 | $1.3M | $16.2M86 |
| 2026 | Justin Leong | $752.9K | $4.6M86 | |
| 2026 | Brett Sandercock | $600.2K | $3.8M86 | |
| 2026 | Aaron Bloomer | $114.5K | $3.5M86 | |
| 2026 | Michael Rider | $535.4K | $2.5M86 | |
| 2025 | Chief executive officer | $1.2M | $14.7M86 | |
| 2025 | Chief product officer | $677.0K | $3.9M86 | |
| 2025 | Former chief financial officer and special advisor to CEO | $499.0K | $3.6M86 | |
| 2025 | Global general counsel and secretary | $508.7K | $2.3M86 | |
| 2024 | Chief executive officer | $1.2M | $14.1M86 | |
| 2024 | Chief product officer | $586.3K | $3.6M86 | |
| 2024 | Former chief financial officer and special advisor to CEO | $471.0K | $3.2M86 | |
| 2024 | Global general counsel and secretary | $489.6K | $2.2M86 |
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | $2.4B | 0.0% | +223,171 |
| Vanguard Capital Management LLC | 9,474,129 | $1.8B | 0.0% | +7,713 |
| Vanguard Portfolio Management LLC | 7,913,661 | $1.5B | 0.1% | +49,739 |
| State Street Corp | 6,680,735 | $1.3B | 0.0% | +37,567 |
| Geode Capital Management, LLC | 4,352,320 | $845.2M | 0.0% | −553 |
| Bank of New York Mellon Corp | 4,197,610 | $818.0M | 0.1% | −727,776 |
| First Trust Advisors LP | 2,278,696 | $444.1M | 0.3% | +740,871 |
| Invesco Ltd. | 2,063,578 | $402.1M | 0.0% | +106,964 |
| Morgan Stanley | 1,928,931 | $375.9M | 0.0% | −757,890 |
| Northern Trust Corp | 1,696,674 | $330.6M | 0.0% | −29,019 |
| Nordea Investment Management Ab | 1,388,008 | $269.6M | 0.2% | +354,627 |
| Deutsche Bank Ag\ | 1,322,313 | $257.7M | 0.1% | −100,552 |
| UBS Group AG | 1,289,300 | $251.3M | 0.0% | +562,489 |
| Swedbank AB | 1,274,897 | $248.5M | 0.2% | −75,337 |
| Charles Schwab Investment Management Inc | 1,222,473 | $238.2M | 0.0% | +87,174 |
| Goldman Sachs Group Inc | 1,160,426 | $226.1M | 0.0% | +156,221 |
| Arrowstreet Capital, Limited Partnership | 1,129,739 | $220.2M | 0.1% | +679,489 |
| Dimensional Fund Advisors LP | 1,123,577 | $219.0M | 0.0% | +119,359 |
| Legal & General Group Plc | 942,614 | $183.7M | 0.0% | −47,747 |
| Aqr Capital Management LLC | 910,623 | $177.1M | 0.1% | +560,783 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 858,134 | $167.2M | 0.0% | +9,064 |
| Jpmorgan Chase & Co | 833,536 | $165.4M | 0.0% | +128,389 |
| Vanguard Fiduciary Trust Co | 814,716 | $158.8M | 0.0% | −10,360 |
| Bank Of America Corp /de/ | 775,424 | $151.1M | 0.0% | −153,006 |
| Citigroup Inc | 774,425 | $150.9M | 0.1% | +384,343 |
13F reports cover disclosed long positions in U.S. stocks only.
16 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 27, 2026 | Alan ArmstrongRepublican, Senate | Buy | $1,001 - $15,000 | −11.8% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Jun 4, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +32.6% | Report |
| Apr 28, 2025 | Kelly MorrisonDemocratic, House | Sale | $1,001 - $15,000 | +36.7% | Report |
| Jan 13, 2025 | Robert P. Bresnahan, Jr.Republican, House | Sale | $1,001 - $15,000 | +27.6% | Report |
| May 3, 2024 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +39.3% | Report |
| Oct 17, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −6.2% | Report |
| Aug 29, 2023 | Thomas R Carper, Senate | Buy | $1,001 - $15,000 | −24.1% | Report |
| Jan 11, 2023 | Thomas R Carper, Senate | Sale | $1,001 - $15,000 | +82.2% | Report |
| Oct 5, 2022 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +100.2% | Report |
| Mar 30, 2022 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −71.0% | Report |
| Oct 26, 2021 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +78.8% | Report |
| Jul 9, 2020 | Thomas R Carper, Senate | Partial sale | $1,001 - $15,000 | +120.4% | Report |
| Apr 2, 2020 | Thomas R Carper, Senate | Partial sale | $1,001 - $15,000 | +145.1% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
How ResMed is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
SC 13G (30), 3 (27), DEFA14A (18), S-8 (16), 424B3 (13), SD (13), 8-K/A (12), UPLOAD (12), CORRESP (7), ARS (5), 10-K/A (4), PRE 14A (4), 5 (3), SCHEDULE 13G (3), SCHEDULE 13G/A (3), 3/A (2), DEFR14A (2), S-3 (2), 10-Q/A (1), 144/A (1), 8-A12B (1), 8-A12G (1), NO ACT (1), POS AM (1), REGDEX (1), S-3/A (1)
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.004 per share | RMD | New York Stock Exchange |
From the cover page of the 10-K filed Aug 13, 2026 (Section 12(b) of the Exchange Act).17
The risks ResMed names in Item 1A of its 10-K filed Aug 13, 2026: 38 risks under these headings, as written.17
We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. See Note 15 – Legal Actions, Contingencies and Commitments of the Notes to Consolidated Financial Statements (Part II, Item 8) included in this report, which is incorporated by reference herein.
Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.
The opening of Item 3, Legal Proceedings.17
The numbers on this page point here. Each one links to the record it came from.
